http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#Head
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#assertion
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#provenance
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#pubinfo
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#assertion
http://purl.obolibrary.org/obo/DOID_9182
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9182
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00635
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association
http://www.w3.org/2000/01/rdf-schema#label
indications and usage prednisone tablets are indicated in the following conditions endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in collagen diseases during an exacerbation or as maintenance therapy in selected cases of dermatologic diseases pemphigus allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as respiratory diseases symptomatic sarcoidosis hematologic disorders idiopathic thrombocytopenic purpura in adults neoplastic diseases for palliative management of edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus gastrointestinal diseases to tide the patient over a critical period of the disease in nervous system acute exacerbations of multiple sclerosis miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00635
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#provenance
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#pubinfo
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#sig
http://purl.org/nanopub/x/hasSignature
DSNXiRHQAV3QW5w0L5ScJppgwJ4nluer4DMoeCICFAFSLguWlIpxPTx5sV2svKldjvrgqzrtfgjWmBfxVh586If5VQLX/xEveQuPacWmCVW37XMSSWXi0/I1MpiRjYr0j+9ZkX+/HigjoexfsGkmtzw3MQ8UhyU4xD/g8mVnBdE=
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
http://purl.org/dc/terms/created
2021-06-13T12:54:01.486+02:00
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs